News Conference News PARTNER Cohort B: TAVR Remains Superior to Standard Therapy at 2 Years November 09, 2011
News Conference News BRAVO: Fewer Adverse Events with Bivalirudin vs. Heparin After Aortic Valvuloplasty November 07, 2011
News Conference News PARTNER: TAVI Cost Effective Compared With Standard Care Jason Kahn April 03, 2011